IDH1 and Cowden syndrome 1: However, the study by Suijker et al. [42] with the AGI-5198 agent—the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants—showed that the use of mutated IDH inhibitors may not always be efficient for the treatment of operable or metastasized CS patients [42].